Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine-Reference-Cited by-同舟云学术

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: Current understanding and perspectives on engineered BCG vaccine

Published:2013-01 Issue:1 Volume:104 Page:22-27
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kawai Koji¹,Miyazaki Jun¹,Joraku Akira¹,Nishiyama Hiroyuki¹,Akaza Hideyuki²

Affiliation:

1. Department of Urology; Faculty of Medicine; University of Tsukuba; Tokyo; Japan

2. Department of Strategic Investigation on Comprehensive Cancer Network; Research Center for Advanced Science and Technology; The University of Tokyo; Tokyo; Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.12075/fullpdf

Reference62 articles.

1. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story;Herr;J Urol,2008

2. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors;Morales;J Urol,1976

3. Bladder cancer: epidemiology, staging and grading, and diagnosis;Kirkali;Urology,2005

4. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update;Babjuk;Eur Urol,2011

5. Bladder carcinoma in situ in 2003: state of the art;Witjes;Eur Urol,2004

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment;Journal of Zhejiang University-SCIENCE B;2024-07

2. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment;International Journal of Molecular Sciences;2024-05-17

3. Exposure of Bladder Cancer Cells to Blue Light (λ = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine;International Journal of Molecular Sciences;2024-04-29

4. Perfusion drugs for non‑muscle invasive bladder cancer (Review);Oncology Letters;2024-04-15